This article reviews the immunologic basis of clinical trials that test means of tumor antigen
recognition and immune activation, with the goal to provide the clinician with a mechanistic …

These are exciting times for the field of cancer immunotherapy. Although the clinical efficacy
of monoclonal antibodies has been demonstrated since the early 1990s, the therapeutic …

It has been more than 100 years since the first reported attempts to activate a patient's
immune system to eradicate developing cancers. Although a few of the subsequent vaccine …

Therapeutic vaccines are currently at the forefront of medical innovation. Various endeavors
have been made to develop more consolidated approaches to producing nucleic acid …

The therapeutic potential of host-specific and tumour-specific immune responses is well
recognized and, after many years, active immunotherapies directed at inducing or …

Progress in tumor immunology has not been translated to effective immunotherapies for
cancer. Most of the current effort in basic and clinical research concentrates on generating …

The goal of vaccine-based cancer immunotherapy is to induce a tumor-specific immune
response that ultimately reduces tumor burden. However, the immune system is often …

The development of cancer vaccines, aimed to enhance the immune response against a
tumor, is a promising area of research. A better understanding of both the molecular …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

Throughout the past 3 decades, along with the recognition that the immune system not only
influences oncogenesis and tumor progression, but also determines how established …